BridgeBio Oncology Therapeutics, Inc. BBOT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001869105

None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $448.4M
Warnings	short runway, thin data not computable: dilution, degenerate inputs, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Mar 5, 2026 241 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$2.63 2026-10-30; market equity $210.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

BBOT is a clinical-stage biotechnology company with the mission of transforming the lives of patients with cancers driven by RAS and PI3K?, the two most frequently mutated oncogenes. Aberrant RAS signaling drives uncontrolled tumor growth in some of the deadliest cancers, including lung, breast, pancreas and colon cancer. This can come from mutations in RAS itself, which underlie approximately 30% of all human cancers, or from RAS-mediated overactivation of PI3K?. Our goal is to provide meaningful benefit to patients by designing and developing new therapies to achieve high levels of target inhibition against these oncogenic drivers while maintaining a favorable tolerability profile.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 56.2						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(6.6%)	(6.6%)		56.2	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 26.2						
Twelve-month failure probability	0.13%	0.08%		60.0	246	2026-06-30
Altman Z double-prime	12.61	(0.35)		7.0	748	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	12.34x	2.92x		11.6	829	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 2						
Net share issuance, one year	not computable	2.5%				
two annual share counts are required; found 1						

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 4.3 months
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(65.7%)	(2.2%)	10
Distance from 52-week high	(80.9%)	(28.7%)	9
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(54.5%)	(1.0%)	13
Book value to price	1.54	0.28	92
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.24)	(0.19)	10

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$54.1M
Operating cash flow, four quarters	-$151.3M
Months of runway	4.3
Days since last periodic filing	82 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$2.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$134.0M	2025-12-31	2026-03-05	10-K	26-094112
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$113.9M	2025-12-31	2026-03-05	10-K	26-094112
3	assets	us-gaap:Assets	$448.4M	2025-12-31	2026-03-05	10-K	26-094112
4	assets	us-gaap:Assets	$164.3M	2024-12-31	2026-03-05	10-K	26-094112
5	current assets	us-gaap:AssetsCurrent	$432.4M	2025-12-31	2026-03-05	10-K	26-094112
6	current liabilities	us-gaap:LiabilitiesCurrent	$35.0M	2025-12-31	2026-03-05	10-K	26-094112
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$356.6M	2025-12-31	2026-03-05	10-K	26-094112
8	operating income	us-gaap:OperatingIncomeLoss	-$145.8M	2025-12-31	2026-03-05	10-K	26-094112
9	book equity	us-gaap:StockholdersEquity	$411.1M	2025-12-31	2026-03-05	10-K	26-094112
10	liabilities	us-gaap:Liabilities	$37.3M	2025-12-31	2026-03-05	10-K	26-094112
11	shares outstanding	dei:EntityCommonStockSharesOutstanding	80,032,823	2026-03-02	2026-03-05	10-K	26-094112

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.